KLK1 and benign prostatic hyperplasia: Therefore, our current experimental results indeed suggest that KLK1 can alleviate inflammation and thereby reduce prostate fibrosis, but in the complex process of human BPH development, this kind of help is limited, and other mechanisms need to be combined to treat BPH.